Orchid genotyping deal smells sweet to Quest:
This article was originally published in Clinica
Orchid BioSciences has licensed its proprietary SNP-IT technology for gene-based diagnostics testing services to Quest Diagnostics. Orchid received an initial fee and will earn royalties on all tests performed by Quest using the technology. The deal offered by Princeton, New Jersey-based Orchid is non-exclusive, and covers tests using SNAPShot reagent kits marketed by Applied Biosystems. Orchid Diagnostics, a newly formed strategic subunit led by COO Donald Marvin, says dealing with a company of the stature of Quest illustrates its success in providing biomedical applications to the entire spectrum of users - from early stage R&D to patients.